472 related articles for article (PubMed ID: 33067414)
41. Smoldering multiple myeloma: when to observe and when to treat?
Mateos MV; San Miguel JF
Am Soc Clin Oncol Educ Book; 2015; ():e484-92. PubMed ID: 25993213
[TBL] [Abstract][Full Text] [Related]
42. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D
J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347
[TBL] [Abstract][Full Text] [Related]
43. Using Both Lactic Dehydrogenase Levels and the Ratio of Involved to Uninvolved Free Light Chain Levels as Risk Factors Improves Risk Assessment in Patients With Newly Diagnosed Multiple Myeloma.
Guo Z; Li H; Geng Y; Cui J; Tang N; Li D
Am J Med Sci; 2018 Apr; 355(4):350-356. PubMed ID: 29661348
[TBL] [Abstract][Full Text] [Related]
44. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies.
Landgren O
Hematology Am Soc Hematol Educ Program; 2013; 2013():478-87. PubMed ID: 24319222
[TBL] [Abstract][Full Text] [Related]
45. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
[TBL] [Abstract][Full Text] [Related]
46. Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria.
Fouquet G; Snell KI; Guidez S; Schraen S; Boyle E; Renaud L; Desmier D; Machet A; Moya N; Systchenko T; Gruchet C; Decaux O; Arnulf B; Fohrer C; Richez V; Kolb B; Macro M; Karlin L; Royer B; Pegourie B; Hebraud B; Caillot D; Perrot A; Moreau P; Facon T; Avet-Loiseau H; Dejoie T; Hulin C; Harding S; Leleu X
Leuk Lymphoma; 2018 Mar; 59(3):583-589. PubMed ID: 28697637
[TBL] [Abstract][Full Text] [Related]
47. [Imaging in smoldering (asymptomatic) multiple myeloma. Past, present and future].
Bhutani M; Landgren O
Radiologe; 2014 Jun; 54(6):572, 574-81. PubMed ID: 24927659
[TBL] [Abstract][Full Text] [Related]
48. The consultant's guide to smoldering multiple myeloma.
Thorsteinsdottir S; Kristinsson SY
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):551-559. PubMed ID: 36485144
[TBL] [Abstract][Full Text] [Related]
49. Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies.
Visram A; Cook J; Warsame R
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):673-681. PubMed ID: 34889380
[TBL] [Abstract][Full Text] [Related]
50. Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma.
Gran C; Liwing J; Wagner AK; Verhoek A; Gezin A; Alici E; Nahi H
Am J Hematol; 2021 Jan; 96(1):23-30. PubMed ID: 32936979
[TBL] [Abstract][Full Text] [Related]
51. Risk Stratification of Precursors to Multiple Myeloma in 2020.
Chudasama R; Barth P
R I Med J (2013); 2020 Apr; 103(3):46-47. PubMed ID: 32236162
[TBL] [Abstract][Full Text] [Related]
52. Advances in the management of asymptomatic myeloma.
Mateos MV
Curr Opin Oncol; 2014 Nov; 26(6):670-6. PubMed ID: 25210868
[TBL] [Abstract][Full Text] [Related]
53. Involved/uninvolved heavy/light chain index can predict progression in transplanted multiple myeloma patients.
Espiño M; Arteche-López A; Medina S; Muñoz-Calleja C; Blanchard MJ; Alegre A; López-Jiménez FJ; Villar LM
Bone Marrow Transplant; 2017 Aug; 52(8):1206-1207. PubMed ID: 28581457
[No Abstract] [Full Text] [Related]
54. Smoldering multiple myeloma: to treat or not to treat.
Gentile M; Offidani M; Vigna E; Corvatta L; Recchia AG; Morabito L; Martino M; Morabito F; Gentili S
Expert Opin Pharmacother; 2015 Apr; 16(6):785-90. PubMed ID: 25659943
[TBL] [Abstract][Full Text] [Related]
55. Smoldering multiple myeloma.
Gao M; Yang G; Kong Y; Wu X; Shi J
Biomed Res Int; 2015; 2015():623254. PubMed ID: 26000300
[TBL] [Abstract][Full Text] [Related]
56. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
van Rhee F; Bolejack V; Hollmig K; Pineda-Roman M; Anaissie E; Epstein J; Shaughnessy JD; Zangari M; Tricot G; Mohiuddin A; Alsayed Y; Woods G; Crowley J; Barlogie B
Blood; 2007 Aug; 110(3):827-32. PubMed ID: 17416735
[TBL] [Abstract][Full Text] [Related]
57. Evolving diagnostic criteria for multiple myeloma.
Rajkumar SV
Hematology Am Soc Hematol Educ Program; 2015; 2015():272-8. PubMed ID: 26637733
[TBL] [Abstract][Full Text] [Related]
58. The road to treating smoldering multiple myeloma.
Korde N; Mailankody S; Landgren O
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S59-64. PubMed ID: 25486957
[TBL] [Abstract][Full Text] [Related]
59. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
González-Calle V; Mateos MV
Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380
[TBL] [Abstract][Full Text] [Related]
60. Prediction of response and progression in multiple myeloma with serum free light chains assay: corroboration of the serum free light chain response definitions.
Khoriaty R; Hussein MA; Faiman B; Kelly M; Kalaycio M; Baz R
Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):E10-3. PubMed ID: 20223721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
